GI Dynamics Release: EndoBarrier® Therapy Data Published in Annals of Surgery

LEXINGTON, Mass. & Sydney--(BUSINESS WIRE)--GI Dynamics, Inc. (ASX: GID) announced today that the Annals of Surgery Journal published results on the Company’s first study evaluating the efficacy and safety of 12 months of EndoBarrier®Therapy in an obese and mostly non-diabetic patient population. The results from this study, previously presented at the International Federation for the Surgery of Obesity and Metabolic Disorders 2010 World Congress, found that EndoBarrier Therapy, a breakthrough treatment for type 2 diabetes and/or obesity, produced an average of 20 percent total body weight loss and significant improvements in cardiovascular risk factors and metabolic functions.

Back to news